Carisma Therapeutics Inc
Carisma Therapeutics is pioneering the development of CAR-Macrophages, a disruptive immunotherapy approach that leverages macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy to treat human diseases, especially solid tumors. Their innovative technology aims to activate both innate and adaptive immune systems to improve cancer treatment outcomes.
Industries
Nr. of Employees
small (1-50)
Carisma Therapeutics Inc
Philadelphia, Pennsylvania, United States, North America
Patents
Method of increasing tumor killing activity of macrophages or monocytes comprising chimeric antigen receptor
US-11739297-B2
View Details
Method of increasing tumor killing activity of macrophages or monocytes comprising chimeric antigen receptor
US-11739297-B2
View DetailsProducts
Pipeline of engineered macrophage therapeutic candidates
A portfolio of engineered macrophage-based cell therapy candidates designed to target solid tumors by combining direct tumor clearance, phenotype programming, and activation of adaptive immunity.
Pipeline of engineered macrophage therapeutic candidates
A portfolio of engineered macrophage-based cell therapy candidates designed to target solid tumors by combining direct tumor clearance, phenotype programming, and activation of adaptive immunity.
Services
Provision of information and pathways for patient participation in active and upcoming clinical trials of engineered macrophage-based therapies.
Provision of information and pathways for patient participation in active and upcoming clinical trials of engineered macrophage-based therapies.
Expertise Areas
- Macrophage-based immunotherapy
- Chimeric antigen receptor (CAR) engineering
- Adoptive cell therapy development
- Tumor microenvironment modulation
Key Technologies
- Chimeric antigen receptors (CARs)
- Macrophage genetic engineering
- Adoptive cellular therapy
- Phenotype programming (M1 macrophage)
News & Updates
Carisma Therapeutics is initiating a Phase I clinical trial of CAR Monocyte targeting HER2-positive cancers, marking a significant step in their development of CAR-Macrophage therapies.
An article discussing CAR-Macrophages as a new approach in cancer immunotherapy, highlighting Carisma Therapeutics' innovative work.
Carisma Therapeutics is initiating a Phase I clinical trial of CAR Monocyte targeting HER2-positive cancers, marking a significant step in their development of CAR-Macrophage therapies.
An article discussing CAR-Macrophages as a new approach in cancer immunotherapy, highlighting Carisma Therapeutics' innovative work.